S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
S&P 500   4,337.44 (+0.40%)
DOW   34,006.88 (+0.13%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:CMMB

Chemomab Therapeutics (CMMB) Earnings Date, Estimates & Call Transcripts

$0.91
-0.01 (-1.09%)
(As of 09/25/2023 ET)
Compare
Today's Range
$0.90
$0.94
50-Day Range
$0.92
$1.42
52-Week Range
$0.90
$5.35
Volume
15,615 shs
Average Volume
366,790 shs
Market Capitalization
$10.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Earnings Summary

Upcoming
Earnings Date
Nov. 10Estimated
Actual EPS
(Aug. 14)
-$0.72 Beat By $0.08
Consensus EPS
(Aug. 14)
-$0.80
Skip Charts & View Estimated and Actual Earnings Data

CMMB Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CMMB Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Chemomab Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231($0.80)($0.80)($0.80)
Q2 20231($0.40)($0.40)($0.40)
Q3 20231($0.40)($0.40)($0.40)
Q4 20231($0.40)($0.40)($0.40)
FY 20234($2.00)($2.00)($2.00)
Q1 20241($0.02)($0.02)($0.02)
Q2 20241($0.02)($0.02)($0.02)
Q3 20241($0.02)($0.02)($0.02)
Q4 20241($0.02)($0.02)($0.02)
FY 20244($0.08)($0.08)($0.08)

CMMB Earnings Date and Information

Chemomab Therapeutics last issued its earnings results on August 14th, 2023. The reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.08. Chemomab Therapeutics has generated ($2.94) earnings per share over the last year (($2.94) diluted earnings per share). Earnings for Chemomab Therapeutics are expected to grow in the coming year, from ($2.40) to ($1.80) per share. Chemomab Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 10th, 2023 based off prior year's report dates.

Chemomab Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/10/2023
Estimated)
------- 
8/14/2023Q2 2023($0.80)($0.72)+$0.08($0.72)--
5/11/2023Q1 2023($0.80)($0.80)-($0.80)--
3/20/2023Q4 2022($0.80)($0.72)+$0.08($0.72)--
11/11/2022Q3 2022($0.60)($0.70)($0.10)($0.70)--
8/12/2022Q2 2022($0.60)($0.54)+$0.06($0.54)--
5/12/2022Q1 2022($0.40)($0.44)($0.04)($0.44)--
3/9/2022Q4 2021($0.40)($0.44)($0.04)($0.44)--
11/11/2021Q3 2021($0.02)($0.26)($0.24)($0.26)--
8/12/2021Q2 2021($0.27)($0.26)+$0.01($0.26)--
5/12/2021Q1 2021($0.43)($0.22)+$0.21($0.22)--
3/9/2021Q4 2020($8.00)($4.00)+$4.00($4.00)--
11/16/2020Q3 2020($7.20)($5.60)+$1.60($5.60)--












Chemomab Therapeutics Earnings - Frequently Asked Questions

When is Chemomab Therapeutics's earnings date?

Chemomab Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, November 10th, 2023 based off last year's report dates. Learn more on CMMB's earnings history.

Did Chemomab Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Chemomab Therapeutics (NASDAQ:CMMB) reported ($0.72) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.80) by $0.08. Learn more on analysts' earnings estimate vs. CMMB's actual earnings.

How much profit does Chemomab Therapeutics generate each year?

Chemomab Therapeutics (NASDAQ:CMMB) has a recorded net income of -$27.65 million. CMMB has generated -$2.94 earnings per share over the last four quarters.

What is Chemomab Therapeutics's EPS forecast for next year?

Chemomab Therapeutics's earnings are expected to grow from ($2.40) per share to ($1.80) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:CMMB) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -